Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,985 public trials 746 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site Newport Beach, California, United States
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site Rolling Hills Estates, California, United States
View all 137 locations
View Trial Details
Completed

Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02299375

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Mendoza, Argentina
  • GSK Investigational Site Mendoza, Argentina
  • GSK Investigational Site San Miguel de Tucumán, Argentina
View all 36 locations
View Trial Details
Completed

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676

Conditions
Cardiovascular Diseases, Chronic Disease, Disease Attributes, +6 more
Locations
  • GSK Investigational Site Andalusia, Alabama, United States
  • GSK Investigational Site Athens, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
View all 1611 locations
View Trial Details
Completed

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

NCT01462344

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Mobile, Alabama, United States
  • GSK Investigational Site Montgomery, Alabama, United States
View all 530 locations
View Trial Details
Completed

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

NCT01313650

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Ormond Beach, Florida, United States
  • GSK Investigational Site Tampa, Florida, United States
View all 165 locations
View Trial Details
Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

NCT02233543

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +6 more
Locations
  • Novartis Investigative Site Aarhus, Denmark
  • Novartis Investigative Site Hvidovre, Denmark
  • Novartis Investigative Site Bergen, Norway
  • Novartis Investigative Site Gothenburg, Sweden
View Trial Details
Completed

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

NCT01475721

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • GSK Investigational Site Athens, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
View all 808 locations
View Trial Details
Completed

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318

Conditions
Asthma, Bronchial Diseases, Eosinophilia, +12 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Fresno, California, United States
  • GSK Investigational Site Long Beach, California, United States
View all 144 locations
View Trial Details

Related conditions